Rivaroxaban Plus Aspirin Shows Favorable Benefit-Risk Profile in PAD Patients after revascularization, suggests study
The VOYAGER PAD trial evaluated the efficacy and safety of rivaroxaban plus aspirin compared to aspirin alone in patients with symptomatic peripheral artery disease (PAD) undergoing lower extremity revascularization procedures. Recently, the US Food and Drug Administration requested additional quantitative benefit-risk analyses to inform decision-making. The researchers have found in a new study that in […]